ReviewFrontiers in nutrition2025
An umbrella review of meta-analyses on the low-FODMAP diet in IBS.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Constipation with bloating: a clinical approach to evaluation and management.Annals of medicine · 2026Review
- Article
- Nutritional Management of Irritable Bowel Syndrome.Nutrients · 2026Review
- Immune-nutritional interactions in endometriosis: current evidence and future perspectives in disease management.Frontiers in immunology · 2026Review
- Advances in the mechanism of low FODMAP diet in the treatment of irritable bowel syndrome: a review.Frontiers in nutrition · 2026Review
- Probiotics in irritable bowel syndrome: strain-specific effects, diet, and biomarker timing.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This umbrella review systematically evaluated the effects of the low FODMAP diet on irritable bowel syndrome (IBS) through 192 studies retrieved from PubMed, Web of Science, Cochrane Library, and Scopus up to January 2025. All meta-analyses and evaluation criteria adhered to PRISMA guidelines. The quality of the included meta-analyses was evaluated by AMSTAR-2. The effect size was expressed as a standardized mean difference, odds ratio, or relative risk, as available. Pooled analysis was based on a random-effects model. Sixteen meta-analyses qualified for the final statistical analysis (141 studies included, 9,904 patients), all of which concerned patients with IBS. Analysis of evidence showed that the low FODMAP diet in IBS patients significantly reduced symptom scores on the IBS Symptom Severity Scale (IBS-SSS) (standardized mean difference (SMD) = -0.599, 5 meta-analyses, 3,761 patients) and improved quality of life (SMD = 0.259,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.